Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Net Income data on record, last reported at -$27.1 million in Q3 2025.

  • For Q3 2025, Net Income fell 13.5% year-over-year to -$27.1 million; the TTM value through Sep 2025 reached $20.9 million, up 117.54%, while the annual FY2024 figure was -$72.7 million, 46.29% up from the prior year.
  • Net Income reached -$27.1 million in Q3 2025 per GLUE's latest filing, down from -$12.3 million in the prior quarter.
  • Across five years, Net Income topped out at $46.9 million in Q1 2025 and bottomed at -$35.2 million in Q2 2023.
  • Average Net Income over 3 years is -$18.2 million, with a median of -$30.3 million recorded in 2024.
  • The widest YoY moves for Net Income: up 246.65% in 2025, down 13.5% in 2025.
  • A 3-year view of Net Income shows it stood at -$33.3 million in 2023, then skyrocketed by 140.39% to $13.4 million in 2024, then plummeted by 301.63% to -$27.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$27.1 million in Q3 2025, -$12.3 million in Q2 2025, and $46.9 million in Q1 2025.